News of Note—Trevena CMO exit; AMO deal; Kala IPO; AliveCor-Mayo pact

Thursday's news from across biopharma

> Small cap Trevena sent out a long press release this morning but waited until the end to report that its chief medical officer, David Soergel, M.D., is “planning to depart from the company in late August to pursue a new opportunity.” The hunt is on for a new CMO, the biotech said, but its shares were down premarket by 4% on the update. Statement

> AMO Pharma has penned a new license deal with private U.K. biopharma Numedicus to work on a glutamate modulator, AMO-04, as well as related compounds, for the treatment of Rett syndrome and certain breathing disorders. Financial terms were not disclosed. Release

> MIT professor Bob Langer’s Kala Pharmaceuticals has hit a $90 million IPO on the Nasdaq, pricing mid-range at $15 under the ticker "KALA." The ophthalmic drug R&D shop is eyeing the cash to equip itself to file for approvals of corticosteroid nanosuspension KPI-121 in two indications. Renaissance Capital brief


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Vic Gundotra, CEO of startup AliveCor and a former executive at Google, says his company is joining forces with the Mayo Clinic to develop tools to screen for a heart rhythm condition that can cause so-called “sudden death”. CNBC story

Suggested Articles

Avidity Biosciences is on a roll—after inking an R&D deal with Eli Lilly and hiring a new CEO, the company is reeling in $100 million.

What the NASH field needs, says Genfit CEO Pascal Prigent, is something like the Hb1Ac test for diabetes.

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.